CD80 and cancer: developed a high-affinity human monoclonal immunoglobulin G1 antibody (MPDL3280A) that specifically binds PD-L1 for clinical use to block PD-L1 and its ligands PD-1 or B7.1 (CD80), so as to achieve the purpose of enhancing the anti-cancer immunity of patients.